Suchergebnisse - "Yoshii, Hidenori"

PubPharm (97)

1

Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus : A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2024

von Fukuda, M. | Sakuma, I. | Wakasa, Y. | +12

2

Continuous glucose monitoring-derived time in range and CV are associated with altered tissue characteristics of the carotid artery wall in people with type 2 diabetes

enthalten in: Diabetologia | 2023

von Mita, T. | Katakami, N. | Okada, Y. | +12

3

Continuous glucose monitoring-derived time in range and CV are associated with altered tissue characteristics of the carotid artery wall in people with type 2 diabetes

enthalten in: Diabetologia | 2023

von Mita, T. | Katakami, N. | Okada, Y. | +12

4

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors : Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2023

von Sugawara, M. | Fukuda, M. | Sakuma, I. | +87

5

Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes : an extension of the SPEAD-A study

enthalten in: Scientific reports | 2023

von Mita, T. | Katakami, N. | Yoshii, H. | +13

6

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)

enthalten in: Diabetes therapy | 2023

von Sugawara, M. | Fukuda, M. | Sakuma, I. | +11

7

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)

enthalten in: Diabetes therapy | 2023

von Sugawara, M. | Fukuda, M. | Sakuma, I. | +11

8

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)

enthalten in: Diabetes therapy | 2023

von Sugawara, M. | Fukuda, M. | Sakuma, I. | +11

9

Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia : A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study)

enthalten in: Nutrients | 2023

von Tamura, Y. | Kaga, H. | Abe, Y. | +6

10

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease : a 2-year extension study of the UTOPIA trial

enthalten in: Cardiovascular diabetology | 2023

von Katakami, N. | Mita, T. | Yoshii, H. | +81

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]